Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
First Claim
1. A method for treating a neurodegenerative cognitive disorder, wherein the neurodegenerative disease cognitive disorder is selected from the group consisting of Alzheimer'"'"'s Disease, Dementia with Lewy Bodies, Parkinson'"'"'s Disease, Fronto-temporal dementia, and Progressive Supranuclear Palsy, comprising administering to a patient a therapeutic amount of glycopyrrolate and a therapeutic amount of rivastigmine.
1 Assignment
0 Petitions
Accused Products
Abstract
A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression. In one preferred embodiment, the disease is dementia with Lewy Bodies. New formulations for quaternary ammonium anti-cholinergic muscarinic receptor antagonists are also disclosed.
-
Citations
10 Claims
- 1. A method for treating a neurodegenerative cognitive disorder, wherein the neurodegenerative disease cognitive disorder is selected from the group consisting of Alzheimer'"'"'s Disease, Dementia with Lewy Bodies, Parkinson'"'"'s Disease, Fronto-temporal dementia, and Progressive Supranuclear Palsy, comprising administering to a patient a therapeutic amount of glycopyrrolate and a therapeutic amount of rivastigmine.
- 5. A method for treating Dementia with Lewy Bodies comprising administering to a patient a therapeutic amount of glycopyrrolate and from about 1.5 to about 24 mg/day orally, or about 4.6 to about 17.4 mg/day by transdermal patch of rivastigmine.
- 7. A method for treating a neurodegenerative cognitive disorder, wherein the neurodegenerative disease cognitive disorder is selected from the group consisting of Alzheimer'"'"'s Disease, Dementia with Lewy Bodies, Parkinson'"'"'s Disease, Fronto-temporal dementia, and Progressive Supranuclear Palsy, comprising administering to a patient a therapeutic amount of glycopyrrolate and a therapeutic amount of donepezil.
Specification